相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC).
M. G. Kris et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Circulating tumor cells in breast cancer: A tool whose time has come of age
Ramona F. Swaby et al.
BMC MEDICINE (2011)
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20
Gong Tang et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Molecular Predictors of Response to Therapy for Breast Cancer
Natalie Galanina et al.
CANCER JOURNAL (2011)
Circulating Tumors Cells as Biomarkers Progress Toward Biomarker Qualification
Daniel C. Danila et al.
CANCER JOURNAL (2011)
The BATTLE to Personalize Lung Cancer Prevention through Reverse Migration
Kathryn A. Gold et al.
CANCER PREVENTION RESEARCH (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Targeting BRAF in Advanced Melanoma: A First Step toward Manageable Disease
Adina Vultur et al.
CLINICAL CANCER RESEARCH (2011)
Circulating Tumor Cells as Biomarkers in Prostate Cancer
Daniel C. Danila et al.
CLINICAL CANCER RESEARCH (2011)
Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer
Francesca Molinari et al.
CLINICAL CANCER RESEARCH (2011)
Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non-Small Cell Lung Cancer Treated with Erlotinib
Linda Mileshkin et al.
CLINICAL CANCER RESEARCH (2011)
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Early Prediction of Nonprogression in Advanced Non-Small-Cell Lung Cancer Treated With Erlotinib By Using [18F]Fluorodeoxyglucose and [18F]Fluorothymidine Positron Emission Tomography
Thomas Zander et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
J. Jean Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application
Soo-Youn Lee et al.
JOURNAL OF PATHOLOGY (2011)
Accelerated Approval of Oncology Products: The Food and Drug Administration Experience
John R. Johnson et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Targeting the missing links for cancer therapy
Kornelia Polyak et al.
NATURE MEDICINE (2011)
Taming the dragon: genomic biomarkers to individualize the treatment of cancer
Ian J. Majewski et al.
NATURE MEDICINE (2011)
Cancer genomics: from discovery science to personalized medicine
Lynda Chin et al.
NATURE MEDICINE (2011)
Integrating predictive biomarkers and classifiers into oncology clinical development programmes
Robert A. Beckman et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The BATTLE Trial: A Bold Step toward Improving the Efficiency of Biomarker-Based Drug Development
Eric H. Rubin et al.
CANCER DISCOVERY (2011)
Mutational Heterogeneity in Human Cancers: Origin and Consequences
Jesse J. Salk et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2010)
Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study
Sandra J. Horning et al.
BLOOD (2010)
The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee
Lesley Seymour et al.
CLINICAL CANCER RESEARCH (2010)
The Cross-Validated Adaptive Signature Design
Boris Freidlin et al.
CLINICAL CANCER RESEARCH (2010)
Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents
Janet E. Dancey et al.
CLINICAL CANCER RESEARCH (2010)
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer
Torsten O. Nielsen et al.
CLINICAL CANCER RESEARCH (2010)
Is F-18-FDG PET/CT Useful for the Early Prediction of Histopathologic Response to Neoadjuvant Erlotinib in Patients with Non-Small Cell Lung Cancer?
Tjeerd S. Aukema et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Comparing Breast Cancer Risk Assessment Models
Mitchell H. Gail et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Randomized Clinical Trials With Biomarkers: Design Issues
Boris Freidlin et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
A policy approach to the development of molecular diagnostic tests
Kevin A. Schulman et al.
NATURE BIOTECHNOLOGY (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Biomarker-adaptive clinical trial designs
Boris Freidlin et al.
PHARMACOGENOMICS (2010)
Accumulation of driver and passenger mutations during tumor progression
Ivana Bozic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The Role of the Microenvironment in Mammary Gland Development and Cancer
Kornelia Polyak et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Noninvasive Evaluation of Oral Lesions Using Depth-sensitive Optical Spectroscopy
Richard A. Schwarz et al.
CANCER (2009)
Biomarker-Driven Early Clinical Trials in Oncology A Paradigm Shift in Drug Development
Daniel S. W. Tan et al.
CANCER JOURNAL (2009)
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
Ji Luo et al.
CELL (2009)
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
A. D. Barker et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Optimising the design of phase II oncology trials: The importance of randomisation
Mark J. Ratain et al.
EUROPEAN JOURNAL OF CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group
Steven M. Teutsch et al.
GENETICS IN MEDICINE (2009)
Imaging Surrogates of Tumor Response to Therapy: Anatomic and Functional Biomarkers
Binsheng Zhao et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Perspectives on the development of imatinib and the future of cancer research
Brian J. Druker
NATURE MEDICINE (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Matthew G. Vander Heiden et al.
SCIENCE (2009)
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Kornelia Polyak et al.
NATURE REVIEWS CANCER (2009)
Breast tumor heterogeneity: causes and consequences
K. Polyak et al.
BREAST CANCER RESEARCH (2009)
Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective
Shashi Amur et al.
BIOMARKERS IN MEDICINE (2008)
Molecular subtypes in breast cancer evaluation and management: Divide and conquer
Jeffrey Peppercorn et al.
CANCER INVESTIGATION (2008)
Randomized phase III clinical trial designs for targeted agents
Antje Hoering et al.
CLINICAL CANCER RESEARCH (2008)
Development and validation of biomarker classifiers for treatment selection
Richard Simon
JOURNAL OF STATISTICAL PLANNING AND INFERENCE (2008)
Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design
Margaret S. Pepe et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Stromal Gene Signatures in Large-B-Cell Lymphomas
G. Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Optical imaging for cervical cancer detection: solutions for a continuing global problem
Nadhi Thekkek et al.
NATURE REVIEWS CANCER (2008)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Biornarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs
J. A. Wagner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Epidermal growth factor receptor inhibitors in non-small cell lung cancer
Janet E. Dancey
DRUGS (2007)
Cancer as an evolutionary and ecological process
Lauren M. F. Merlo et al.
NATURE REVIEWS CANCER (2006)
Converting a breast cancer microarray signature into a high-throughput diagnostic test
Annuska M. Glas et al.
BMC GENOMICS (2006)
The US food and drug administration perspective on cancer biomarker development
Steven Gutman et al.
NATURE REVIEWS CANCER (2006)
Progress in chemoprevention drug development: The promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - A plan to move forward
Gary J. Kelloff et al.
CLINICAL CANCER RESEARCH (2006)
Fit-for-purpose method development and validation for successful biomarker measurement
JW Lee et al.
PHARMACEUTICAL RESEARCH (2006)
Bayesian clinical trials
DA Berry
NATURE REVIEWS DRUG DISCOVERY (2006)
Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients
B Freidlin et al.
CLINICAL CANCER RESEARCH (2005)
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development
G Kelloff et al.
CLINICAL CANCER RESEARCH (2005)
New science-based endpoints to accelerate oncology drug development
GJ Kelloff et al.
EUROPEAN JOURNAL OF CANCER (2005)
On the efficiency of targeted clinical trials
A Maitournam et al.
STATISTICS IN MEDICINE (2005)
Candidate-based proteomics in the search for biomarkers of cardiovascular disease
L Anderson
JOURNAL OF PHYSIOLOGY-LONDON (2005)
Human cancer, PTEN and the PI-3 kinase pathway
R Parsons
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2004)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
PTEN function: how normal cells control it and tumour cells lose it
NR Leslie et al.
BIOCHEMICAL JOURNAL (2004)
The biology and clinical relevance of the PTEN tumor suppressor pathway
I Sansal et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Comparison of treatment response classifications between unidimensional, bidimensional, and volumetric measurements of metastatic lung lesions on chest computed tomography
LN Tran et al.
ACADEMIC RADIOLOGY (2004)
Reanalysis of cancer drugs: Old drugs, new tricks
GFV Woude et al.
CLINICAL CANCER RESEARCH (2004)
Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development
JW Park et al.
CLINICAL CANCER RESEARCH (2004)
Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus
CC Maley et al.
CANCER RESEARCH (2004)
Positron emission tomography in non-small-cell lung cancer: Prediction of response to chemotherapy by quantitative assessment of glucose use
WA Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Clinical biomarkers in drug discovery and development
R Frank et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
分享论文
